Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

On Wednesday, Relmada Therapeutics, Inc. RLMD announced a preplanned interim analysis of the Reliance II Phase 3 study.Reliance II is designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder (MDD), to be used in combination with other approved anti-depressants.The Independent Data Monitoring Committee (DMC) analysis indicated that the Reliance II Phase 3 study is futile and unlikely to meet the primary efficacy endpoint with statistical significance.No new safety signals were r ...